Friday 6 November 2026
Export DNTH’s income statement to Excel — free account
Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
86.43
3.42
+4.12%
Follow DNTH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 4 | 4 | 4 |
| (38.38%) | (22.70%) | (26.07%) | (22.61%) | ||
| (35.88%) | (21.77%) | (24.98%) | (21.81%) | ||
ROIC |
(124.80%) | (132.76%) | (47.74%) | (36.55%) | |
Return on Tangible Assets |
(42.83%) | (16.05%) | (22.26%) | (24.40%) | |
Average Days of Receivables |
9.32 | 336.04 | 20.32 | 78.16 | |
Free Cash Flow per Share |
(3.35) | (2.72) | (2.78) | (3.07) | |
Free Cash Flow |
(129.27) | (130.48) | (155.71) | (175.85) | |
Capital Expenditures |
(0.21) | (0.20) | (0.33) | (0.70) | |
| Other line items | |||||
Cash ROIC |
(14.40%) | (5.64%) | (7.56%) | (8.46%) | |
Accounts Receivable Turnover |
4.74 | 1.20 | 26.26 | 0.97 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
7,153.14% | 11,464.30% | 9,222.58% | 6,942.94% | |
Selling, General and Administrative Expense of Revenue |
1,686.20% | 2,953.74% | 2,318.80% | 1,840.95% | |
Share Based Compensation of Revenue |
1,119.50% | 2,101.80% | 1,800.00% | 1,515.78% | |
Operating CF/Net income |
0.80 | 0.75 | 0.81 | 0.87 | |
Depreciation/Fixed assets |
(19.37) | (18.65) | (23.11) | (10.97) | |
Capex/Depreciation |
0.04 | 0.04 | 0.03 | 0.08 | |
Revenue per Share |
0.05 | 0.03 | 0.03 | 0.05 | |
Operating CF per Share |
(3.34) | (2.71) | (2.77) | (3.05) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.10 | 0.15 | 0.18 | 0.26 |
Columns are period end dates · fundamentals updated 6 Nov 2026